Start Over

Serum levels of L1-ORF1p and airflow limitation.

Authors :: Guerra S
Vasquez MM
Bojang P Jr
Ramos IN
Sherrill DL
Martinez FD
Halonen M
Ramos KS
Source :: ERJ open research [ERJ Open Res] 2019 Nov 25; Vol. 5 (4). Date of Electronic Publication: 2019 Nov 25 (Print Publication: 2019).
Publication Year :: 2019
Abstract: In a population-based study, higher circulating levels of L1-ORF1p were associated with lower lung function levels and increased risk for airflow limitation among former smokers http://bit.ly/2ZEIjNv.<br />Competing Interests: Conflict of interest: S. Guerra reports grants from the NIH during the conduct of the study. Conflict of interest: M.M. Vasquez has nothing to disclose. Conflict of interest: P. Bojang Jr has patent WO2017172839A1 (Use of biomarkers associated with LINE-1) issued. Conflict of interest: I.N. Ramos has nothing to disclose. Conflict of interest: D.L. Sherrill has nothing to disclose. Conflict of interest: F.D. Martinez reports grants from the National Institutes of Health (NIH)/National Heart, Lung and Blood Institute (HL139054, HL056177, HL132523, HL091889, HL130045 and HL098112), NIH/National Institute of Environmental Health Sciences (ES006694), NIH/National Institute of Allergy and Infectious Diseases (AI126694), NIH/Office of Director (OD023282) and Johnson & Johnson (UA009253-0001), and personal fees for consultancy from Copeval and Commense Inc., outside the submitted work. Conflict of interest: M. Halonen reports grants from the National Institutes of Health during the conduct of the study. Conflict of interest: K.S. Ramos reports grants from the National Institutes of Health during the conduct of the study. He holds patent W02017172839A1 (Use of biomarkers associated with LINE-1) and patent 2019 62/787444 (Systems and methods for characterizing and treating disease).<br /> (Copyright ©ERS 2019.)